3156-20-5

Basic information

• Product Name: 2-(4-bromo-phenoxymethyl)-1H-benzoimidazole
• Synonyms: 2-(4-bromo-phenoxymethyl)-1H-benzoimidazole
• CAS NO: 3156-20-5
• Molecular Weight: 303.158
• Mol File: 3156-20-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(4-bromo-phenoxymethyl)-1H-benzoimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromo-phenoxymethyl)-1H-benzoimidazole(3156-20-5)
• EPA Substance Registry System: 2-(4-bromo-phenoxymethyl)-1H-benzoimidazole(3156-20-5)

Safety Data

• Hazardous Substances Data: 3156-20-5(Hazardous Substances Data)

Usage

Type of compound

Benzimidazole derivative

Contains

A bromo group and a phenoxy methyl group

Properties

Aromatic and heterocyclic

Potential applications

Pharmaceutical and agrochemical industries

Potential applications

Medicine and agriculture (based on further research)

Possible biological activities

Antiviral, anticancer, and antibacterial properties

Use

As a building block in drug discovery and development

Upstream product

• 1878-91-7 (4-bromophenoxy)acetic acid 
• 95-54-5 1,2-diamino-benzene 

Relevant articles and documents

1-ethyl gallate-2-substituted phenoxymethyl benzimidazoles: Synthesis, molecular structure, antimicrobial activities and complex with Cr(III)

Summary: The design of gallate and benzimidazole containing derivatives is expected to produce new bioactive molecules with multiple applications. Here the synthesis of eight novel benzimidazole compounds containing ethyl gallate and substituted phenoxyme

Inhibition of Rat Hepatic Microsomal Aminopyrine N-Demethylase Activity by Benzimidazole Derivatives. Quantitative Structure-Activity Relationships

Eighty-two benzimidazole derivatives have been prepared and tested for the ability to inhibit cytochrome P-450 mediated enzyme activity (aminopyrine N-demethylase) from phenobarbitone-induced rat hepatic microsomes.Using physicochemical parameters and multiple regression analysis, we derived a quantitative structure-activity relationship (QSAR) that describes up to 87percent of the data variance in terms of hydrophobic and electronic effects and the molar refractivity of the substituent in the 2-position of the benzimidazole ring.